Ever Supreme Take a Successful Debut on 2019 Taiwan Healthcare Expo - ESG

Ever Supreme Take a Successful Debut on 2019 Taiwan Healthcare Expo

Ever Supreme shows an abundance of research and development capacities with dazzling results
Ever Supreme Bio Technology Co., LTD (6712) (hereinafter referred to as Ever Supreme) will participate in the Taiwan Healthcare Expo 2019 in Nangang Exhibition Hall from December 5 to December 8. Ever Supreme demonstrates great potentials with researches and technologies, and strong team works on developing new cell drugs to Taiwan and the oversea. In terms of Regulations on Governing Specific Cellular Therapeutic Technology (RGSCTT), numbers of the cell therapy approved by the Taiwan TFDA is outstanding in performance.

Ever Supreme has received the FDA-approval orphan drug designation on dendritic cell vaccine "ADCV01" for treating malignant brain tumors, the applications filed by collaborated medical institute China Medical University to TFDA under the RGSCTT was approved by the TFDA in May and September on "Stage IV solid cancers" and "Stages I to III solid cancers after ineffective conventional treatment" on eight types of cancers. Ever Supreme is the first biotechnology company in Taiwan to be approved with dendritic cell therapy to treat cancer patients with various stages.

Ever Supreme had made a splendid result under RGSCTT, for which more than 600 people have been consulted with. The number on contracts signed has reached more than 40 and continues to increase. Ever Supreme also develops its own products, such as bone marrow mesenchymal stem cells (BMSC) and cytokines-Induced killer (CIK) cells, a combined therapy of dendritic cells and cytokine-induced killer cells (DC-CIK), and more than a dozen of medical institutions have jointly applied for the collaborated projects aiming for striving on increasing patient vitality and improvement of patient health.

Regarding to the development of new drugs, Ever Supreme has the ability to develop independently, and to deploy a complete layout plan on immune cell and stem cell development by technology transfers on various cell therapy technologies with China Medical University and Sinica Academy:
1. In the area of immune cells, the dendritic cell vaccine (ADCV01) for the treatment of malignant brain tumors was approved by the Taiwan FDA for Phase II clinical trials on May 2019 and patients are currently being recruited.
2. In the area of stem cells, the Phase I clinical trial of allogeneic umbilical cord mesenchymal stem cells (UMSC01) for the treating acute myocardial infarction (AMI) was approved by the US FDA on February 2018 and by Taiwan FDA in September in the same year. Clinical trials are currently ongoing.
Ever Supreme has three cell preparation sites and currently we are hastily expanding the third site. It is being constructed to comply with the highest PIC/S GMP standard. In the future, these three sites will operate concurrently, and the capacity to produce will be impressive.

Ever Supreme is conceptualized with people-oriented in principals, and to combine front-end R&D with back-end advanced medical technologies offered by medical institutions. We are committed to promoting various public welfare undertakings, fulfilling corporate social responsibilities, and benefiting the public health.